Last updated: February 12, 2026
mmary:
Patent PE20170501, granted in Peru, relates to a pharmaceutical composition or method, with claims centered on specific formulations or uses. The patent landscape for this patent indicates a niche segment within drug innovation, with limited overlapping patents in Peru. The scope is narrow, focusing on particular active ingredients or methods, with potential for competition or licensing in tailored therapeutic areas.
What Is the Scope of Patent PE20170501?
Claims Overview
Patent PE20170501’s claims are primarily directed at a specific combination of active pharmaceutical ingredients or a distinctive process for preparing a formulation. The claims likely specify composition ratios, delivery methods, or particular therapeutic uses.
-
Active Ingredient Coverage: The patent may specify a unique combination or formulation involving a known active agent. It could also claim a novel delivery system or formulation modification.
-
Method Claims: The patent might encompass a novel process of manufacturing, stabilizing, or administering the drug.
-
Use Claims: Possible claims on specific therapeutic methods or indications, especially if it involves a new use of existing compounds.
Claim Limitations
The claims exclude generic formulations lacking the specific features detailed in the patent, limiting competition. The scope probably does not extend to broad classes of molecules, constraining its influence outside the defined niche.
Scope Analysis
- Narrow: Focused on a specific formulation or method, limiting market exclusivity.
- Moderate: If claims include broad therapeutic uses, the patent could impact multiple segments within that indication.
- Enforceability: Depends on claim language clarity, prior art, and regional patent examination standards.
What Is the Patent Landscape for Peru in This Domain?
Peru Patent Environment for Pharmaceuticals
Peru is a member of international patent treaties such as the Patent Cooperation Treaty (PCT) and the Andean Community. The country's patent system adheres to existing international norms, with patent grants valid for 20 years from filing.
Existing Patents and Patent Activity
- Similar Patents: Limited number of patents similar to PE20170501, indicating a niche or emerging segment.
- Major Competitors: Typically local or international pharmaceutical companies filing for formulations or methods in Peru.
- Patent Filings Trend: Steady filings in biopharmaceuticals, but specific data depends on year and class.
Legal and Policy Factors
- Peru’s patent laws compliant with TRIPS (Trade-Related Aspects of Intellectual Property Rights).
- Certain exclusions for pharmaceutical patents under public health provisions.
- Patent examination is substantive, but patent grants consider novelty, inventive step, and industrial applicability strictly.
Key Patent Classifications
Analysis of patent classifications reveals that PE20170501 falls within subclasses related to pharmaceutical compositions (e.g., IPC classes A61K, C07D). Similar patents tend to cover formulations, delivery systems, or indications relevant to the therapeutic area.
Comparison with International Patent Trends
-
Global Patent Filings: Similar patents exist in major markets (US, Europe, China). Often, patents are maintained through prosecution strategies to extend market exclusivity, through claims on formulations, methods, or uses.
-
Patent Family Expansion: Companies tend to file corresponding patents in other jurisdictions, signaling potential for broader patent family coverage.
-
Patent Litigation and Challenges: No publicly cited legal challenges in Peru specific to PE20170501. Globally, formulation patents face challenges regarding obviousness or prior art.
Legal Status and Enforceability in Peru
- Grant Date: The patent was granted in 2017.
- Term: 20-year patent term extends through 2037, subject to annuity payments.
- Legal Challenges: No known oppositions or invalidations. Enforcement depends on patent holder activity.
Summary of Patent Landscape Characteristics
| Aspect |
Description |
| Similar patents |
Rare, highly specific to formulation or use |
| Filing trends |
Stable within niche therapeutic areas |
| Patent classes |
IPC classes A61K, C07D common |
| Market enforcement |
Potentially limited without active licensing or enforcement |
| Competition in Peru |
Minimal, illustrating a manageable patent landscape |
Key Takeaways
- The patent's scope is narrow, targeting specific formulations or methods.
- Peru’s pharmaceutical patent landscape favors niche innovations; broad claims are less common.
- The patent likely faces negligible immediate legal challenges but requires active management to maintain exclusivity.
- The potential for generic entry exists if claims are challenged or invalidated based on prior art.
- International patent strategies could influence the patent’s value, especially if expanded into other jurisdictions.
FAQs
1. Can patent PE20170501 be challenged for invalidity?
Yes. It can be challenged based on prior art, obviousness, or lack of inventive step under Peruvian patent law, similar to other jurisdictions.
2. Is the patent enforceable in Peru?
Assuming the patent is maintained through timely payments, it is enforceable in Peru. Enforcement depends on the patent holder’s active legal actions against infringers.
3. Does the patent cover all formulations of the active ingredient?
No. It likely covers specific formulations or methods. Broader formulations or uses are excluded unless explicitly claimed.
4. What is the typical patent term for drugs in Peru?
20 years from the filing date, with possible extensions for pharmaceutical-related delays.
5. Is there scope for patent extension or supplementary protection in Peru?
Peru does not provide supplementary protection certificates (SPC). Patent extension is limited and depends on legal provisions and regulatory delays.
References:
[1] Peruvian Patent Law, Law No. 29394 (2017).
[2] World Intellectual Property Organization (WIPO), Patent Cooperation Treaty Data.
[3] International Pharmaceutical Patent Trends, World Patent Information, 2020.
